Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies

Journal of Cutaneous Medicine and Surgery

Volumn 9, Issue 5, 2005, Pages 209-214

  Gupta, Aditya K ^a,b,c   Davey, Valerie ^b   McPhail, Heather ^b   Hart, David A ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD;

ACTINIC KERATOSIS; CANADA; CAUCASIAN; CLINICAL TRIAL; CREAM; CRYOTHERAPY; DRUG DOSE REGIMEN; DRUG EFFICACY; FACE; FOLLOW UP; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SCALP; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; SYSTEMATIC REVIEW; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; CLINICAL TRIALS, PHASE III; CONFIDENCE INTERVALS; FACIAL DERMATOSES; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON INDUCERS; KERATOSIS; OINTMENTS; PHOTOSENSITIVITY DISORDERS; SCALP DERMATOSES; TIME FACTORS;

EID: 33747596885     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-005-0148-6     Document Type: Review

References (55)

1. Feldman SR, Fleischer AB Jr, McConnell RC. Most common dermatologic problems identified by internists, 1990-1994. Arch Intern Med 1998; 158:726-730.
2. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002; 70:30-36.
3. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:8-10.
4. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:4-7.
5. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000; 42:25-28.
6. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995; 32:95-98.
7. Feldman SR, Fleischer AB Jr, Williford PM, et al. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol 1999; 40:43-47.
8. Marks R. The role of treatment of actinic keratoses in the prevention of morbidity and mortality due to squamous cell carcinoma. Arch Dermatol 1991; 127:1031-1033.
9. Dillaha CJ, Jansen GT, Honeycutt WM, et al. Further studies with topical 5-fluorouracil. Arch Dermatol 1965; 92:410-417.
10. Gupta AK, Weiss JS, Jorizzo JL. 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin Therapy Lett 2001; 6:1-4.
11. Jansen GT. Topical therapy with 5-fluorouracil. J Surg Oncol 1971; 3:317-323.
12. Jeffes EW III, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol 2000; 1:167-179.
13. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002; 70:335-339.
14. Rossman RE. Topical fluorouracil therapy. South Med J 1969; 62:1240-1242.
15. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002; 70:22-29.
16. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol 1970; 101:132-139.
17. Dahl MV. Imiquimod: an immune response modifier. J Am Acad Dermatol 2000; 43:S1-S5.
18. Dahl MV. Imiquimod: a cytokine inducer. J Am Acad Dermatol 2002; 47:S205-S208.
19. Rosso JQDel. An update on newer topical therapies for actinic keratoses: advances and applications. J Drugs Dermatol 2003; 2:35-39.
20. Stanley MA. Mechanism of action of imiquimod. Papillomavirus Rep 1999; 10:23-29.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
22. Velanovich V. Meta-analysis for combining Bayesian probabilities. Med Hypotheses 1991; 35:192-195.
23. Breza T, Taylor R, Eaglstein WH. Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol 1976; 112:1256-1258.
24. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51:547-555.
25. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131:176-181.
26. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50:714-721.
27. Shuttleworth D, Marks R. A comparison of the effects of intralesional interferon alpha-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease. J Dermatol Treat 1989; 1:65-68.
28. Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144:1050-1053.
29. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138:1498-1502.
30. Abadir DM. Combination of topical 5-fluorouracil with cryotherapy for treatment of actinic keratoses. J Dermatol Surg Oncol 1983; 9:403-404.
31. Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study. Br J Dermatol 1987; 116:549-552.
32. Bianchi L, Campione E, Marulli GC, et al. Actinic keratosis treated with an immune response modifier: a ease report of six patients. Clin Exp Dermatol 2003; 28(Suppl 1):39-41.
33. Chen K, Yap LM, Marks R, et al. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol 2003; 44:250-255.
34. Eklind J, Tartler U, Maschke J, et al. Imiquimod to treat different cancers of the epidermis. Dermatol Surg 2003; 29:890-896.
35. Epstein E. Treatment of lip keratoses (actinic cheilitis) with topical fluorouracil. Arch Dermatol 1977; 113:906-908.
36. Kurwa HA, Yong-Gee SA, Seed PT, et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999; 41:414-418.
37. Labandeira J, Pereiro M Jr, Valdes F, et al. Intermittent topical 5-fluorouracil is effective without significant irritation in the treatment of actinic keratoses but prolongs treatment duration. Dermatol Surg 2004; 30:517-520.
38. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24:990-1000.
39. Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991; 25:665-667.
40. Persaud A, Lebwohl M. Imiquimod cream in the treatment of actinic keratoses. J Am Acad Dermatol 2002; 47:S236-S239.
41. Persaud AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002; 47:553-556.
42. Robins P. Pulse therapy with 5-FU in eradicating actinic keratoses with less than recommended dosage. J Drugs Dermatol 2002; 1:25-30.
43. Robinson TA, Kligman AM. Treatment of solar keratoses of the extremities with retinoic acid and 5-fluorouracil. Br J Dermatol 1975; 92:703-706.
44. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol 2002; 47:571-577.
45. Smith S, Piacquadio D, Morhenn V, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003; 2:629-635.
46. Warnock GR, Fuller RP Jr, Pelleu GB Jr. Evaluation of 5-fluorouracil in the treatment of actinic keratosis of the lip. Oral Surg Oral Med Oral Pathol 1981; 52:501-505.
47. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol 1995; 48:167-171.
48. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001; 323:42-46.
49. Mulrow C, Langhorne P, Grimshaw J. Integrating heterogeneous pieces of evidence in systematic reviews. Ann Intern Med 1997; 127:989-995.
50. Silapunt S, Goldberg LH, Alam M. Topical and light-based treatments for actinic keratoses. Semin Cutan Med Surg 2003; 22:162-170.
51. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther 2001; 23:908-920.
52. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther 2001; 23:901-907.
53. Levy S, Furst K, Chern W. A novel 0.5% fluorouracil cream is minimally absorbed into the systemic circulation yet is as effective as 5% fluorouracil cream. Cutis 2002; 70:14-21.
54. Simmonds WL. Topical management of actinic keratoses with 5-fluorouracil: results of a 6-year follow-up study. Cutis 1972; 10:737-742.
55. Robins P, Gupta AK. The use of topical fluorouracil to treat actinic keratosis. Cutis x 2002; 70:4-7.